Profile:
Actelion US is a biopharmaceuticals company headquartered in Switzerland, focusing on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs. ZAVESCA® (miglustat) is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not therapeutic option (e.g. due to constraints such as a allergy hypersensitivity, or poor venous access)

Categories

THERAPEUTICS

Biopharmaceuticals